[Expectant treatment of placenta previa with ritodrine].
OBJECTIVE
To investigate the effectiveness of the expectant treatment in placenta previa with adrenergic agonist ritodrine.


METHODS
50 women with placenta previa of preterm labor were randomly assigned into two groups. 26 patients treated with magnesium sulfate were served as control group. 24 patients were enrolled in the study group, receiving ritodrine 100 mg in 5% glucose 500 ml intravenous. The drip speed was started at 8 drips per minute routinely, then adjusted according to the treatment response, and oral ritodrine was used after vaginal bleeding and uterine contraction disappeared 12 hours. If contraction reappeared, the i.v. infusion would be restarted.


RESULTS
The study group prolonged the gestational period to an average of 28.24 days and increased the birth weight of newborn to an average of 2,913.68 g (P < 0.05).


CONCLUSIONS
Ritodrine is highly effective and safe for expectant treatment of placenta previa.
Lu
H
H
Foshan Women and Children Hospital, Guangdong Foshan.
Guo
X
X
Zheng
Y
Y
D000318:Adrenergic beta-Agonists / Q000627:therapeutic use*; D000328:Adult; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D010923:Placenta Previa / Q000188:drug therapy*; D011247:Pregnancy; D012312:Ritodrine / Q000627:therapeutic use*
D000318:Adrenergic beta-Agonists; D012312:Ritodrine